Skip to main content
RT @AdelaCastro222: The new IL-17A/F inhibitor, bimekizumab, was comparable to current established therapies in active #

Adela Castro AdelaCastro222

3 years 10 months ago
The new IL-17A/F inhibitor, bimekizumab, was comparable to current established therapies in active #AnkylosingSpondylitis. Check our NMA poster today. #ACR22 #SpA #medtwitter @TheBold_MD @cplch19 @UTSWRheum @ACRheum @RheumNow @DrCassySims https://t.co/vxa05r0GvS
RT @Yuz6Yusof: #ACR22 Abstr#0359 Is 2021 DORIS remission attainable in #lupus? Pooled analyses of Anifrolumab RCTs showe

Md Yuzaiful Md Yusof Yuz6Yusof

3 years 10 months ago
#ACR22 Abstr#0359 Is 2021 DORIS remission attainable in #lupus? Pooled analyses of Anifrolumab RCTs showed this was met in ~10% patients in treatment group vs 3% placebo. Faster and sustained too @Rheumnow https://t.co/5MY2O8i2gA https://t.co/PUeUY25JZl
RT @AdelaCastro222: #ACR22 Raynaud’s:
💡Primary RP is the most common
💡Autoimmune RP is rare! Other causes more c

Adela Castro AdelaCastro222

3 years 10 months ago
#ACR22 Raynaud’s: 💡Primary RP is the most common 💡Autoimmune RP is rare! Other causes more common: metabolic, trauma, vibration, Buergers. 💡NMA showed that both CCB and PDE5i reduced frequency and severity of symptoms 💡Supportive measures are cornerstone! @ACRheum @RheumNow https://t.co/tb5FEmHJDz
RT @DrTrishHarkins: “For the secret of the care of the patient is in caring for the patient”
- Francis W Peabody

W

Patricia Harkins DrTrishHarkins

3 years 10 months ago
“For the secret of the care of the patient is in caring for the patient” - Francis W Peabody What a poignant end to a fantastic key note speech by Dr Abraham Verghese! #ACR22 @RheumNow https://t.co/R6Z1h8em7n
RT @KDAO2011: "One more thing you need in a story-- Epiphany, where the soul of the commonest object seems radiant" - Dr

TheDaoIndex KDAO2011

3 years 10 months ago
"One more thing you need in a story-- Epiphany, where the soul of the commonest object seems radiant" - Dr. Verghese. His #epiphany occurred in the #HIV era helping a dying patient come to terms w/death; he discovered “The doctor can heal without curing.” #ACR22 @rheumnow https://t.co/Yh3SU4AMIZ
RT @drdavidliew: GCA with visual symptoms:
do you hit the pulse iv methylpred button? Why?

260 pts from Lund 🇸🇪
n

David Liew drdavidliew

3 years 10 months ago
GCA with visual symptoms: do you hit the pulse iv methylpred button? Why? 260 pts from Lund 🇸🇪 no doubt some channelling, but: IVMP no better and more steroid exposure/toxicity This adds to existing doubts. Time to seriously question this practice? ABST0459 #ACR22 @RheumNow https://t.co/nbQlhvoRQP
The management of RA patients with a history of cancer continues to be an area of concern. General recommendations are to treat patients with a history of solid organ cancer as no different to any other RA patient. Recently, the ORAL-Surveillance study demonstrated evidence of a greater risk of cancer with tofacitinib than with TNF inhibitors. In this setting, two posters both reassure and raise a new cause for concern.
RT @drdavidliew: Many hoped rituximab would be the panacea for all with IgG4-RD.

Consistent story: it's not.
In this Eu

David Liew drdavidliew

3 years 10 months ago
Many hoped rituximab would be the panacea for all with IgG4-RD. Consistent story: it's not. In this European data: - only 56% in remission at 12m - pancreato-hepato-biliary slightly better, RPF mid-range This story isn't over. We need other options ABST0147 #ACR22 @RheumNow https://t.co/kyIYLLWM9g
RT @EBRheum: Interested in this late-breaker, comparative study of secukinumab (IL17) vs adalimumab (TNF) in AxSpa

No d

Mike Putman EBRheum

3 years 10 months ago
Interested in this late-breaker, comparative study of secukinumab (IL17) vs adalimumab (TNF) in AxSpa No difference in radiographic progression at 1 year - in line with my perception of relative equality for these treatments Need long term data! #ACR22 @rheumnow abstr#L15 https://t.co/7EdhJsW3bq
RT @Janetbirdope: Only 4 minutes to discuss adherence in #SLE. Implementation of discussion if <80% of meds filled. A

Janet Pope Janetbirdope

3 years 10 months ago
Only 4 minutes to discuss adherence in #SLE. Implementation of discussion if <80% of meds filled. Academic docs - 20/24 used + reinforcement, validated in 17 Pts, 11/24 asked open ended ?s. Pts thought it was right timing. ?does it change behaviour- ? Abst0063 @RheumNow #ACR22 https://t.co/UQbRgw5Emj
RT @ericdeinmd: All monster stories end with an unexpected award: A new order
@cuttingforstone at #ACR22 tells the monst

Eric Dein ericdeinmd

3 years 10 months ago
All monster stories end with an unexpected award: A new order @cuttingforstone at #ACR22 tells the monster story of #covid “How will history review our story?” The science will get an A+, but we failed to learn the lessons of history All was predictable through history @RheumNow
RT @DrCassySims: What if a patient is diagnosed with #SLE during #pregnancy?

Abstract #2931 742 women with #lupus

ðŸ¤

Catherine Sims, MD DrCassySims

3 years 10 months ago
What if a patient is diagnosed with #SLE during #pregnancy? Abstract #2931 742 women with #lupus 🤰15 women (2%) had onset of lupus during pregnancy -47% in 2nd trimester, 40% in 3rd 🤰Worse preg. outcomes: fetal demise and preterm delivery (both 13%)
RT @DrPetryna: #ACR22 opening session. Dr.Saag: 50%of rheumatologists expected to retire in the next 10 years reducing o

Olga Petryna DrPetryna

3 years 10 months ago
#ACR22 opening session. Dr.Saag: 50%of rheumatologists expected to retire in the next 10 years reducing our workforce by 25%. Significant concern for access to rheum care lays ahead of us #rheumshortage @RheumNow https://t.co/ECXA2QG0kH
RT @ericdeinmd: @KenSaag, ACR president describes the challenges to rheumatologists including physician shortages and ne

Eric Dein ericdeinmd

3 years 10 months ago
@KenSaag, ACR president describes the challenges to rheumatologists including physician shortages and need for more diversity at #ACR22 opening session. "You cannot be what you cannot see" Room 108 at NOON - find out what @ACRheum and @ACRheumDC will do. @RheumNow @CreakyJoints https://t.co/8KV6vDalNu
RT @Yuz6Yusof: #ACR22 Opening Plenary. Dr Saag championed the importance of funding and support to early career research

Md Yuzaiful Md Yusof Yuz6Yusof

3 years 10 months ago
#ACR22 Opening Plenary. Dr Saag championed the importance of funding and support to early career researchers, team science, translational science and public health @RheumNow https://t.co/pgSZ1twgG3
×